Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Gilead Sciences

    Client Virtual Booth

    GILEAD SCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Gilead Sciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    333 Lakeside Drive Foster City, CA 94404
    Telephone
    Telephone
    +1 650 574 3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gilead.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gilead-sciences/
    Twitter
    Twitter
    https://twitter.com/GileadSciences

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Poseida examines CAR-T conditioning to crack into solid tumors
    Poseida examines CAR-T conditioning to crack into solid tumors

    https://www.fiercebiotech.com/biotech/aacr-bring-car-t-solid-tumors-poseida-thinks-we-need-boost-conditioning-therapy

    Annalee Armstrong FIERCE BIOTECH
    10 Apr 2024
    Share Share
    CG Life snaps up digital agency Toolhouse to double in size
    CG Life snaps up digital agency Toolhouse to double in size

    https://www.fiercepharma.com/marketing/cg-life-adds-toolhouse-portfolio-snapping-digital-agency-double-size

    Nick Paul Taylor FIERCE PHARMA
    09 Apr 2024
    Share Share
    Gilead Sciences to Release First Quarter 2024 Financial Results
    Gilead Sciences to Release First Quarter 2024 Financial Results

    https://www.businesswire.com/news/home/20240408350262/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Teva snares up to $150M in Abingworth funding for inhaler program
    Teva snares up to $150M in Abingworth funding for inhaler program

    https://www.fiercepharma.com/pharma/teva-snares-150m-abingworth-funding-propel-late-stage-asthma-rescue-inhaler

    FIERCE PHARMA
    02 Apr 2024
    Share Share
    Gilead Sciences Champions Equal Pay
    Gilead Sciences Champions Equal Pay

    https://www.accesswire.com/849181/gilead-sciences-champions-equal-pay

    ACCESSWIRE
    02 Apr 2024
    Share Share
    Gilead dives deeper into Nurix protein degrader collab
    Gilead dives deeper into Nurix protein degrader collab

    https://www.fiercebiotech.com/biotech/gilead-dives-deeper-nurix-protein-degrader-collab-paying-15m-2-year-extension

    James Waldron FIERCE BIOTECH
    02 Apr 2024
    Share Share
    Gilead partners for ballroom dancing workshop on sexual health & HIV prevention
    Gilead partners for ballroom dancing workshop on sexual health & HIV prevention

    https://endpts.com/gilead-partners-for-ballroom-dancing-workshop-on-sexual-health-and-hiv-prevention/

    Beth Snyder Bulik ENDPTS
    01 Apr 2024
    Share Share
    FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
    FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

    https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/fda-expands-indication-for-gileads-vemlidy-tenofovir-alafenamide-to-treat-chronic-hbv-infection-in-pediatric-patients-as-young-as-six

    PRESS RELEASE
    29 Mar 2024
    Share Share
    Gilead and Xilio Announce License Agreement for Tumor-Activated IL-12 Program
    Gilead and Xilio Announce License Agreement for Tumor-Activated IL-12 Program

    https://www.businesswire.com/news/home/20240328734624/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    FDA Expands Indication for Gilead's Vemlidy to Treat Chronic HBV Infection
    FDA Expands Indication for Gilead's Vemlidy to Treat Chronic HBV Infection

    https://www.businesswire.com/news/home/20240327502740/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search